Mental Health

Largest Phase 3 Trial of Psilocybin for Depression Has Begun | Psychedelic spotlight

psilocybin for depression
Written by admin

As our social fabric is unraveling and rates of depression continue to rise, affecting an estimated 310 million people worldwide, psilocybin research has given us a glimmer of hope that things may be changing for the better.

The largest Phase 3 clinical trial investigating the safety, efficacy, and tolerability of psilocybin as a treatment for treatment-resistant depression (TRD) has finally begun.